Continuing Access To The Tyrosine Kinase Inhibitor Of VEGFR 2, AG-013736 (A406) For Patients Previously Receiving AG-013736 In Clinical Trials

Trial Profile

Continuing Access To The Tyrosine Kinase Inhibitor Of VEGFR 2, AG-013736 (A406) For Patients Previously Receiving AG-013736 In Clinical Trials

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Jul 2017

At a glance

  • Drugs Axitinib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Expanded access
  • Sponsors Pfizer
  • Most Recent Events

    • 27 Feb 2017 Planned number of patients changed from 53 to 10.
    • 12 Aug 2016 Planned primary completion date changed from 1 Feb 2017 to 1 Feb 2018.
    • 01 May 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top